Posted by Michael Wonder on 07 Mar 2023
DoH makes further tweaks to the agenda for this week's PBAC meeting
7 March 2023 - We are now at version 4 with four revisions.
The late changes are as follows:
- Hyaluronic acid with polyethylene glycol 400 with propylene glycol and hydroxypropyl guar (Systane Hydration) - revised presentation
- Upadacitinib monohydrate (Rinvoq) - to be considered at another PBAC meeting
- Risperidone (Okedi) - to be considered at another PBAC meeting
- Elexacaftor with tezacaftor and ivacaftor and ivacaftor (Trikafta) - late addition
